ChiCTR-ONC-14004779
结束
他氟前列素滴眼液
化药
他氟前列素滴眼液
2014-06-10
/
-
對原發性開角型青光眼、 原發性閉角型青光眼、正常眼壓性青光眼或高眼壓病人施用0.0015% 他氟前列素 (Tafluprost) 滴眼液後的不良反應概況的研究
對原發性開角型青光眼、 原發性閉角型青光眼、正常眼壓性青光眼或高眼壓病人施用0.0015% 他氟前列素 (Tafluprost) 滴眼液後的不良反應概況的研究
To study on the Adverse Effect Profile of the 0.0015% Tafluprost Ophthalmic Solution in Patients with Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma, Normal Tension Glaucoma or Ocular Hypertension.
连续入组
其它
N/A
/
-
/
20
/
2014-06-21
1990-01-01
/
1) Patients diagnosed with primary open angle glaucoma (POAG), primary angle closure glaucoma (PACG), normal tension glaucoma (NTG) or ocular hypertension (OHT); 2) Switching from latanoprost (other concomitant drugs should not be changed 1 month prior to the switch of medication and are continued during the treatment period); 3) Age between 18 to 70 years; 4) Those who can visit the clinic on the designated day as instructed by the physician.；
登录查看1) History of intraocular surgery or laser treatment during the three months before informed consent; 2) History of corneal refractive surgery; 3) History of drug allergy (hypersensitivity) to the drugs to be used during the study period (anesthetic ophthalmic solution, fluorescein, etc.) or similar drugs to the investigational product; 4) Presence of any corneal disorder that may interfere with accurate IOP measurement using applanation tonometer; 5) Female patients who are pregnant, nursing or planning a pregnancy; 6) Patients who need to change their pretreating ophthalmic medications (other than latanoprost) during the study.；
登录查看Santen Pharmaceutical Co., Ltd.
/
全球上市
一致性评价
生产检验昌郁医药2024-11-22
上海和誉生物医药科技有限公司2024-11-22
云顶新耀2024-11-22
金斯瑞生物2024-11-22
细胞与基因治疗领域2024-11-22
肝脏时间2024-11-22
医药笔记2024-11-22
生物安全情报网2024-11-22
医药速览2024-11-22
亚盛医药2024-11-22
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
